Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany

Abstract Background Erenumab, the first-in-class fully human monoclonal antibody targeting the calcitonin gene-related peptide receptor, was shown to be efficacious and safe for the prophylactic treatment of migraine in adults in randomized clinical trials. Large-scale, real-world evidence in multi-...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Andreas Straube, Philipp Stude, Charly Gaul, Katrin Schuh, Mirja Koch
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
R
Acceso en línea:https://doaj.org/article/4f7b5707f3f94856a2b455887d75c33c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!